Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07287150 · ClinicalTrials.gov registry record · Phase 2

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Hoffmann-La Roche.

Recruiting
Registry status
Phase 2
Development phase
100
Enrollment target
10
Study locations

NCT07287150: Recruiting Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Hoffmann-La Roche.

NCT07287150 is a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 100 participants, below the 196-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (49% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07287150, a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Hoffmann-La Roche.

RECRUITING
Registry status
Phase 2
Development phase
100 participants
Enrollment target
10
Study locations

Study Summary

This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) who have received one prior second-generation ARPi.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG Docetaxel
  • DRUG Enzalutamide
  • DRUG Abiraterone
  • DRUG Inavolisib
  • DIAGNOSTIC_TEST Diagnostic test

Study Locations (10)

Other

  • Seoul National University Hospital - Seoul
  • Severance Hospital, Yonsei University Health System - Seoul
  • Asan Medical Center. - Seoul
  • Samsung Medical Center - Seoul

Iowa

  • Holden Comprehensive Cancer Center - Iowa City

South Carolina

  • Carolina Urologic Research Center - Myrtle Beach

Queensland

  • Sunshine Coast University Hospital - Birtinya

Victoria

  • Box Hill Hospital - Box Hill

São Paulo

  • CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia - Santo André

Quebec

  • Jewish General Hospital - Montreal

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2026-03-31
Est. Completion 2029-07-30
Phase Phase 2
Hoffmann-La Roche

909 total trials

What NCT07287150 shows while recruiting

NCT07287150 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 196-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (49% lower).

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.

NCT07287150 lists 10 locations in 7 states (Other, Iowa, South Carolina).

Frequently Asked Questions

What is clinical trial NCT07287150 about?

NCT07287150 is a clinical study titled "A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer". This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) wh...

What is the current status of trial NCT07287150?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2026-03-31. Estimated completion is 2029-07-30.

What conditions does trial NCT07287150 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT07287150?

The interventions under investigation include: Docetaxel (DRUG), Enzalutamide (DRUG), Abiraterone (DRUG), Inavolisib (DRUG), Diagnostic test (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT07287150?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07287150 being conducted?

This trial has 10 study locations across Iowa, South Carolina, Queensland, Victoria, São Paulo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07287150's enrollment target sits among peer trials

100 28th of 69 higher than 41 of 69 other Metastatic Castration-Resistant Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07287150

Source: ClinicalTrials.gov NCT07287150, the US trial registry maintained by the National Library of Medicine. NCT07287150 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.